Are Robust Financials Driving The Recent Rally In Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Stock?

Simply Wall St19:28 ET

Changchun High-Tech Industries (000661.SZ): The clinical trial application for the type II simple herpes virus mRNA vaccine of the controlled subsidiary has been approved.

Gelonghui reported on December 20 that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary - Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "Baike Biotechnology") has received the approval notice for drug clinical trials issued by the National Medical Products Administration. The clinical trial application for the Type II herpes simplex virus mRNA vaccine has been approved. Type II herpes simplex virus infection, which leads to genital herpes, is a contagious disease primarily spread through sexual contact, characterized by easy transmission, recurrence, and a lack of effective cure, becoming a serious public health issue. To prevent the occurrence of genital herpes, already several...

Gelonghui FinanceDec 20 09:13 ET

Changchun High-Tech Industry's Unit Gets Registration Certificate for Luteinizing Hormone Kit

MT NewswiresDec 18 22:33 ET

Changchun High-Tech Industries (000661.SZ): The luteinizing hormone detection kit has obtained the medical instruments registration certificate.

Gelonghui, December 18th丨Changchun High-Tech Industries (000661.SZ) announced that its subsidiary Shanghai SaiZeng Medical Technology Co., Ltd. received the "Medical Instrument Registration Certificate" (in vitro diagnostic reagents) issued by the Shanghai Municipal Drug Administration. Product name: Luteinizing Hormone Test Kit (fluorescent immunochromatography method). The acquisition of this medical instrument registration certificate further enriches the company's product line and will have a positive impact on the company's business development.

Gelonghui FinanceDec 18 05:38 ET

Changchun High-Tech Industry's Unit Gets Nod to Trial Advance Solid Tumors Treatment Tablets

MT NewswiresDec 17 22:54 ET

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 01:21 ET